Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2019-07-15 Regulatory Filings
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)(IgG Fc 도메인을 가지는 융합 단백질의 생산방법)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by Alteogen. It details the patent name, content, and strategic importance for their biosimilar development. Since this is a regulatory announcement of a specific corporate event that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2019-07-15 Korean
기타경영사항(특허권취득)(자율공시)(변형항체를 포함하는 항체-약물 접합체)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by Alteogen. It details the patent name, technical content, and utilization plans. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2019-07-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea for directors and major shareholders to report their shareholdings and changes therein (insider trading). Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-07-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including acquisition methods, share counts, and purposes. This corresponds to the 'Major Shareholding Notification' category.
2019-07-15 Korean
기타경영사항(특허권취득)(자율공시)(IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Alteogen regarding the acquisition of a patent for a stable liquid formulation of a fusion protein. It is categorized as a 'voluntary disclosure' (자율공시) under Korean regulatory standards. Since it does not fit into specific categories like M&A, financial reports, or director dealings, and is a formal regulatory announcement of a corporate event, it falls under the RNS (Regulatory Filings) category.
2019-06-12 Korean
기타경영사항(특허권취득)(자율공시)(IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure ('자율공시') regarding the acquisition of a patent ('특허권 취득') by Alteogen. It details the patent name, content, and strategic utilization plan. Since this is a specific regulatory announcement regarding a corporate event (patent acquisition) that does not fit into categories like financial reports, board changes, or shareholder meetings, it falls under the general regulatory filing category.
2019-05-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.